- Home
- XERS vs CPRI Comparison
XERS vs CPRI Comparison
Compare XERS & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | CPRI |
|---|---|---|
| Founded | 2005 | 1981 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | XERS | CPRI |
|---|---|---|
| Price | $13.32 | $21.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | $12.86 | ★ $23.17 |
| AVG Volume (30 Days) | 2.2M | ★ 3.5M |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 111.40 |
| EPS | N/A | ★ 0.85 |
| Revenue | $49,590,000.00 | ★ $3,474,000,000.00 |
| Revenue This Year | $32.91 | N/A |
| Revenue Next Year | $23.75 | $2.45 |
| P/E Ratio | ★ N/A | $24.98 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $12.40 |
| 52 Week High | $11.42 | $28.27 |
Technical Indicators
Market Signals| Indicator | XERS | CPRI |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 81.01 |
| Support Level | $9.73 | $16.82 |
| Resistance Level | $10.60 | $21.98 |
| Average True Range (ATR) | 0.48 | 0.81 |
| MACD | -0.09 | 0.55 |
| Stochastic Oscillator | 39.36 | 97.55 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 600 company-owned stores, wholesale partners, and online. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold through third-party retailers, e-commerce platforms, and in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.